About: From Biomolecular and Technological Innovations to Clinical Applications - 8th National GOIM Congress., 18-21 June 2006, Messina, Italy

Documentation

scienceplus.abes.fr version Bêta

scienceplus.abes.fr | explorer

À propos de : From Biomolecular and Technological Innovations to Clinical Applications - 8th National GOIM Congress., 18-21 June 2006, Messina, Italy Goto Sponge NotDistinct Permalink

Attributs	Valeurs
type	work Issue
Is Part Of	http://hub.abes.fr/oup/periodical/annonc/2006/volume_17
Title	From Biomolecular and Technological Innovations to Clinical Applications - 8th National GOIM Congress., 18-21 June 2006, Messina, Italy
has manifestation of work	http://hub.abes.fr/oup/periodical/annonc/2006/volume_17/issue_suppl7/m/print http://hub.abes.fr/oup/periodical/annonc/2006/volume_17/issue_suppl7/m/web
Date Copyrighted	2006
Rights	© 2006 European Society for Medical Oncology
issue	suppl_7
is Is Part Of of	Medical treatment of resistant or recurrent epithelial ovarian cancer Significance of P16INK4A hypermethylation gene in primary head/neck and colorectal tumors: it is a specific tissue event? Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study session C Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM) Patterns of K-ras mutation in colorectal carcinomas from Iran and Italy (a Gruppo Oncologico dell'Italia Meridionale study): influence of microsatellite instability status and country of origin Raltitrexed plus levofolinic acid and bolus/continuous infusion 5-fluorouracil on a biweekly schedule for elderly patients with advanced colorectal carcinomas Molecular detection of TP53, Ki-Ras and p16INK4A promoter methylation in plasma of patients with colorectal cancer and its association with prognosis. Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study Primary systemic therapy on local advance breast cancer, where are we going? Taxane-containing chemotherapy in the treatment of early breast cancer patients Y179C, F486L and N550H are BRCA1 variants that may be associated with breast cancer in a Sicilian family: results of a 5-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy session D From adjuvant to preventive breast cancer treatment: bridging the gap over troubled waters Postchemotherapy residual masses in germ cell tumor patients: our experience Guest Editors: session A New strategies in colon cancer adjuvant therapy FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM) session E Oral vinorelbine plus capecitabine (oral vincap) combination in patients with advanced breast cancer (ABC). A phase II study of the GOIM (Gruppo Oncologico dell'Italia Meridionale) BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial From bio-molecular and technology innovations to clinical practice: focus on ovarian cancer Novel P53 mutations detected by FAMA in colorectal cancers Apoptosis: a relevant tool for anticancer therapy Targeting Raf-kinase: molecular rationales and translational issues author index Patterns of genomic instability in gastric cancer: clinical implications and perspectives session B Gastric adenomas: relationship between clinicopathological findings, Helicobacter pylori infection, APC mutations and COX-2 expression Detection and quantification of mammaglobin in the blood of breast cancer patients: can it be useful as a potential clinical marker? Preliminary results of a GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study Methodology of clinical trials with new molecular-targeted agents: where do we stand? session F Nuclear and cytoplasmic interaction of pRb2/p130 and ER-β in MCF-7 breast cancer cells Cetuximab for treatment of metastatic colorectal cancer

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata